-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Preface As a revolutionary innovation, immunotherapy provides a new method for the treatment of non-small cell lung cancer.
Radiotherapy, as an irreplaceable local treatment method in the treatment of lung cancer, can promote the anti-tumor effect of immunotherapy
.
During the 2021 CSCO conference, Yimaitong had the honor to interview Academician Yu Jinming of Shandong Cancer Hospital to share with us the research progress and future development direction of radiotherapy combined immunotherapy
.
Expert profile: Academician Yu Jinming, Academician of the Chinese Academy of Engineering, Dean of Shandong Cancer Hospital, Doctor of Medicine, Ph.
D.
Supervisor Member of the Standing Committee of Shandong Provincial People’s Congress, Deputy Director of Education, Science, Culture and Health, Honorary School (Academic) Dean of Shandong First Medical University (Provincial Academy of Medical Sciences) Central Health Care Expert, President-elect of the Chinese Society of Clinical Oncology (CSCO) Vice-Chairman of the Chinese Anti-Cancer Association Chairman of the Shandong Anti-Cancer Association Chairman of the Oncology Branch of the Shandong Medical Association Chairman of the Shandong Association of Academicians and Experts High-level Shandong Province The president of the Talent Promotion Association, the editor-in-chief or deputy editor-in-chief of many journals such as Chinese Journal of Cancer Prevention and Treatment: Radiotherapy combined with immunotherapy is one of the current research hotspots.
Your team reported on the use of hypersegmentation and An exploratory study of low-dose radiotherapy combined with PD-1/TGF-β dual antibody in the treatment of advanced non-small cell lung cancer with at least second-line failure.
Could you please introduce the overall efficacy and safety? Academician Yu Jinming: Immunotherapy has been rated as a revolutionary innovation and has made great breakthroughs, but at the same time, the resistance of immunological drugs is an unavoidable fact
.
Dual immune therapy can be applied to the resistance of a single immune drug.
If the dual immune therapy is still resistant, then the combination of radiotherapy and immunotherapy may play a role in delivering charcoal in a timely manner, and the two can work together to further improve the efficacy
.
Radiotherapy has two principles for improving immune efficacy: first, radiotherapy kills cells and induces an in situ vaccine effect; second, radiotherapy improves the tumor microenvironment, turning immune "cold" tumors into "hot" tumors
.
We have found that advanced patients who fail first-line treatment often have multiple lesions.
If high-dose radiation is used for multiple lesions, combined with dual immunotherapy, the patient may not be able to tolerate it
.
Therefore, in this study, we gave high doses to large lesions and low doses to small lesions, and combined dual-immune therapy while designing a dose gradient
.
A small number of patients participated in the pre-test of the program and achieved relatively good results
.
Due to the difference in dose gradients and the low toxicity of immunotherapy drugs, the trial has achieved good preliminary results, and we also hope that the final results will be released
.
Yimaitong: Under the new treatment model in the immunotherapy era, what is the position of postoperative radiotherapy in non-small cell lung cancer and the future research direction? Academician Yu Jinming: The use of radiotherapy for lung cancer patients is mainly based on two conditions: first, the primary tumor or metastasis is not completely removed, and the residual tumor is found under the naked eye or through pathology; second, the high-risk potential recurrence and metastasis have a high probability Tumor, or with multiple or multiple lymph node metastasis
.
Therefore, postoperative radiotherapy is actually an auxiliary treatment, which requires us to strictly grasp the indications
.
I think precise diagnosis and precise selection are very important
.
Radiotherapy for stage Ⅲ non-small cell lung cancer after surgery has been based on simple imaging, pathology, and the subjective opinions of surgeons to make decisions today, and today is based on comprehensive factors such as molecular and genetic levels and cell biology to determine the indications for treatment.
This is A process of gradual precision
.
Yimaitong: CSCO has gone through 24 sessions.
What are your expectations for the development of CSCO? Academician Yu Jinming: In fact, along the way of the 24th CSCO, China's tumor career has also grown from small to large, from weak to strong
.
A large number of Chinese original researches emerged in this CSCO conference.
I believe that more and more Chinese elements, Chinese voices, Chinese evidence, and Chinese guides will be displayed on the world stage in the future.
.
We will definitely build on the foundation laid by our predecessors, focus on innovation, inherit the spirit, and unite and help each other.
I also firmly believe in going in China! CSCO must work! Recommended reading 2021 CSCO | Professor Sheng Xinan: Immunization combined with ADC, a new breakthrough in the treatment of metastatic urothelial cancer 2021 CSCO | Professor Guo Jun: Opportunities and challenges of immunotherapy in the treatment of melanoma in China 2021 CSCO | Professor Qin Shukui: Chinese and foreign breakthroughs Research Progress in Sexuality, Reshaping the Pattern of Liver Cancer Treatment 2021 CSCO | Professor Jiang Zefei: Multi-dimensional sharing of progress in the field of breast cancer diagnosis and treatment by CSCO
Radiotherapy, as an irreplaceable local treatment method in the treatment of lung cancer, can promote the anti-tumor effect of immunotherapy
.
During the 2021 CSCO conference, Yimaitong had the honor to interview Academician Yu Jinming of Shandong Cancer Hospital to share with us the research progress and future development direction of radiotherapy combined immunotherapy
.
Expert profile: Academician Yu Jinming, Academician of the Chinese Academy of Engineering, Dean of Shandong Cancer Hospital, Doctor of Medicine, Ph.
D.
Supervisor Member of the Standing Committee of Shandong Provincial People’s Congress, Deputy Director of Education, Science, Culture and Health, Honorary School (Academic) Dean of Shandong First Medical University (Provincial Academy of Medical Sciences) Central Health Care Expert, President-elect of the Chinese Society of Clinical Oncology (CSCO) Vice-Chairman of the Chinese Anti-Cancer Association Chairman of the Shandong Anti-Cancer Association Chairman of the Oncology Branch of the Shandong Medical Association Chairman of the Shandong Association of Academicians and Experts High-level Shandong Province The president of the Talent Promotion Association, the editor-in-chief or deputy editor-in-chief of many journals such as Chinese Journal of Cancer Prevention and Treatment: Radiotherapy combined with immunotherapy is one of the current research hotspots.
Your team reported on the use of hypersegmentation and An exploratory study of low-dose radiotherapy combined with PD-1/TGF-β dual antibody in the treatment of advanced non-small cell lung cancer with at least second-line failure.
Could you please introduce the overall efficacy and safety? Academician Yu Jinming: Immunotherapy has been rated as a revolutionary innovation and has made great breakthroughs, but at the same time, the resistance of immunological drugs is an unavoidable fact
.
Dual immune therapy can be applied to the resistance of a single immune drug.
If the dual immune therapy is still resistant, then the combination of radiotherapy and immunotherapy may play a role in delivering charcoal in a timely manner, and the two can work together to further improve the efficacy
.
Radiotherapy has two principles for improving immune efficacy: first, radiotherapy kills cells and induces an in situ vaccine effect; second, radiotherapy improves the tumor microenvironment, turning immune "cold" tumors into "hot" tumors
.
We have found that advanced patients who fail first-line treatment often have multiple lesions.
If high-dose radiation is used for multiple lesions, combined with dual immunotherapy, the patient may not be able to tolerate it
.
Therefore, in this study, we gave high doses to large lesions and low doses to small lesions, and combined dual-immune therapy while designing a dose gradient
.
A small number of patients participated in the pre-test of the program and achieved relatively good results
.
Due to the difference in dose gradients and the low toxicity of immunotherapy drugs, the trial has achieved good preliminary results, and we also hope that the final results will be released
.
Yimaitong: Under the new treatment model in the immunotherapy era, what is the position of postoperative radiotherapy in non-small cell lung cancer and the future research direction? Academician Yu Jinming: The use of radiotherapy for lung cancer patients is mainly based on two conditions: first, the primary tumor or metastasis is not completely removed, and the residual tumor is found under the naked eye or through pathology; second, the high-risk potential recurrence and metastasis have a high probability Tumor, or with multiple or multiple lymph node metastasis
.
Therefore, postoperative radiotherapy is actually an auxiliary treatment, which requires us to strictly grasp the indications
.
I think precise diagnosis and precise selection are very important
.
Radiotherapy for stage Ⅲ non-small cell lung cancer after surgery has been based on simple imaging, pathology, and the subjective opinions of surgeons to make decisions today, and today is based on comprehensive factors such as molecular and genetic levels and cell biology to determine the indications for treatment.
This is A process of gradual precision
.
Yimaitong: CSCO has gone through 24 sessions.
What are your expectations for the development of CSCO? Academician Yu Jinming: In fact, along the way of the 24th CSCO, China's tumor career has also grown from small to large, from weak to strong
.
A large number of Chinese original researches emerged in this CSCO conference.
I believe that more and more Chinese elements, Chinese voices, Chinese evidence, and Chinese guides will be displayed on the world stage in the future.
.
We will definitely build on the foundation laid by our predecessors, focus on innovation, inherit the spirit, and unite and help each other.
I also firmly believe in going in China! CSCO must work! Recommended reading 2021 CSCO | Professor Sheng Xinan: Immunization combined with ADC, a new breakthrough in the treatment of metastatic urothelial cancer 2021 CSCO | Professor Guo Jun: Opportunities and challenges of immunotherapy in the treatment of melanoma in China 2021 CSCO | Professor Qin Shukui: Chinese and foreign breakthroughs Research Progress in Sexuality, Reshaping the Pattern of Liver Cancer Treatment 2021 CSCO | Professor Jiang Zefei: Multi-dimensional sharing of progress in the field of breast cancer diagnosis and treatment by CSCO
